Back to Basics: Tenets of Testing in Myeloma Diagnostics

Please Log In or Register to continue.

Release Date: December 20, 2016
Expiration Date: December 20, 2017

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The diagnostic and prognostic landscape for myeloma has evolved greatly with the introduction of new criteria per the International Myeloma Working Group, and ongoing research to better define smoldering and active myeloma. In this activity, Dr. Thomas Martin will provide a review of the updated diagnostic criteria, implementation of the Revised International Staging System (R-ISS) in practice, and clinical pearls to reinforce the basics of testing in the diagnosis of myeloma.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in the diagnosis of myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Differentiate between smoldering and active myeloma based on the International Myeloma Working Group criteria
  • Summarize the necessary tests that must be ordered to diagnose a patient with multiple myeloma
  • Explain the appropriate staging of myeloma patients using the Revised International Staging System


Back to Basics: Tenets of Testing in Myeloma Diagnostics – Thomas G. Martin III, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 20, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Thomas G. Martin III, MD
Co-Director, Myeloma Program
University of California, San Francisco (UCSF) Medical Center
Director of the Hematologic Malignancies Research Program
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Dr. Thomas Martin III received his medical degree from the University of Connecticut School of Medicine in Farmington, Connecticut. He completed an internship and residency in internal medicine at Harbor University of California, Los Angeles (UCLA) Medical Center in Torrance, California, and a fellowship in hematology/oncology at the University of California, San Francisco (UCSF) Medical Center. Dr. Martin is currently the Co-Director of the Myeloma Program at the UCSF Medical Center, and the Director of the Hematologic Malignancies Research Program at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Martin is board certified in internal medicine, hematology, and medical oncology. He is a member of the Clinical Research Office of UCSF Cancer Center, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. Dr. Martin has written numerous articles and abstracts, has been an invited lecturer at various symposia, and has served as principal investigator for numerous clinical studies for myeloma, acute leukemia, and stem cell transplantation.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-128-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 16-128-044


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Thomas Martin has received grant support related to research activities from Amgen Inc. and Sanofi.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Celgene Corporation, and Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.